Last checked at 5 Dec 2022 07:00
5 December 2022
Nuformix plc
("Nuformix" or the "Company")
Resignation of Auditor
Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces the resignation of Jeffreys Henry LLP ("Jeffreys Henry") as auditors to the Company. Section 519 of the Companies Act 2006 (the "Act") requires Jeffreys Henry to send a statement of the reasons for ceasing to hold office. They have stated that in accordance with Section 519 of the Act, they are ceasing to hold office due to the following reason:
"Jeffreys Henry LLP have resigned as auditor on the grounds that the firm has taken the decision not to register as an auditor eligible to undertake Public Interest Entity audits."
There are no circumstances connected with Jeffreys Henry ceasing to hold office as auditor which they consider should be brought to the attention of the Company's members or creditors. As required by the Companies Act, Nuformix will send a copy of the resignation letter to shareholders.
The appointment of a new auditor will be announced in due course following the completion of a tender process.
Enquiries:
Nuformix plc |
|
Dr Julian Gilbert, Non-executive Chairman
| Via IFC Advisory
|
Stanford Capital Partners Limited |
|
Tom Price / Patrick Claridge (Corporate Finance) | +44 (0) 20 3650 3650 |
John Howes (Corporate Broking) | +44 (0) 20 3650 3652
|
IFC Advisory Limited |
|
Tim Metcalfe Zach Cohen | +44 (0) 20 3934 6630 nuformix@investor-focus.co.uk |
About Nuformix
Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has a pipeline of preclinical assets with potential for significant value and early licensing opportunities.